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Abstract
Techniques for conditional gene or protein expression are important tools in developmental
biology and in the analysis of physiology and disease. On the protein level, the tunable and
reversible expression of proteins can be achieved by the fusion of the protein of interest to a
destabilizing domain (DD). In the absence of its specific ligand (Shield-1), the protein is
degraded by the proteasome. The DD-Shield system has proven to be an excellent tool to
regulate the expression of proteins of interests in mammalian systems but has not been
applied in teleosts like the medaka. We present the application of the DD-Shield technique
in transgenic medaka and show the ubiquitous conditional expression throughout life.
Shield-1 administration to the water leads to concentration-dependent induction of a YFP
reporter gene in various organs and in spermatogonia at the cellular level.
Introduction
The analysis of gene function in development and in adult organisms requires the controlled
expression of proteins of interest. However, many genes have pleiotropic functions during
embryogenesis and adulthood, hence the expression of a transgene may cause embryonic phe-
notypes that impede the analysis of later developmental stages. Therefore, several conditional
expression systems have been developed to avoid embryonic phenotypes and to restrict the
expression temporally and spatially [1]. Typically, two transgenes are used to control the
expression of the gene of interest. The effector transgene defines the time and tissue of expres-
sion, activating or repressing the target transgene. In combination with transgenic methods to
express fluorescent proteins in specific cell types, the observation of environmental or genetic
effects is possible at the level of tissues or cells [2].
Activation of the target gene can also be achieved by a single transgene using the heat shock
promoter for activation. Heat shock in zebrafish [3] and medaka [4] causes reliable expression
of a transgene, but not all tissues have been tested and not all organs responded to this stress
signal. In the medaka, the gonadal cells failed to activate the transgene upon heat shock treat-
ment [4]. However, gonadal somatic cells and germ cells have been repeatedly labeled by fluo-
rescent proteins in transgenic medaka [5–7]. Hence, the inefficient activation in these cells is
seemingly not related to transgenesis but to a different response to heat shock.
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The DD-Shield-System combines the simplicity of using a single transgene with the dose-
dependent effect of Shield-1 to stabilize the protein of interest [8]. The authors isolated a dou-
ble mutation (F36V, L106P) of the rapamycin-binding protein FKBP12 that confers a high
level of instability to fusion partners of this protein domain and termed it the destabilizing
domain (DD). The specific binding of the synthetic ligand Shield-1 to DD stabilizes the fusion
protein that is otherwise degraded via the proteasome. Remarkably, this degradation is nearly
complete in N-terminal fusions and can be fully restored by the addition of 1 μM Shield-1.
This effect is concentration dependent and little if any side effects could be observed on the
overall gene expression [9]. The system has been extensively tested in cell cultures [8], the pro-
tozoan Entamoeba histolytica [10], the flatworm Caenorhabditis elegans [11], in transgenic
xenografts [12] and transgenic mice [13]. However, the DD-Shield system has not yet been
applied in teleosts like the medaka (Oryzias latipes), which is a unique model organism in
genetics, developmental biology, toxicology and carcinogenesis [14].
In principle, the fine tuning of expression using DD-Shield-1 can be achieved in every cell
that expresses the fusion protein. For an in vivo treatment with any molecule, diffusion barriers
like epithelia or the blood brain barrier may block or diminish the drug availability, change the
kinetics of induction or may actively transport or degrade a drug like Shield-1. In this report
we determined experimentally, whether the DD-Shield system is a practical approach for tun-
able protein expression in the medaka and whether all tissues including the gonads respond to
the treatment.
Materials and Methods
Medaka stocks
Oryzias latipes strains d-rR.YHNI [15], FLFII [16] and FSI [17] were kept under standard con-
ditions [18]. Hybrids of these strains are healthy and fertile and we refer to such hybrids as
‘Ola’ when specific features like the leucophore free locus [19] are not selected for in the breed-
ing process.
This study was carried out according to the German regulations for animal welfare and
approved by the Saxonian government (Landesdirektion Sachsen, 24–9168.11-8/2009-1).
Vectors
Vectors for the Ac/Ds-transposon system [20] were kindly provided by Sergey Parinov, Tema-
sek Life Sciences Laboratory, Singapore. For a nearly ubiquitous expression of a destabilized
yellow fluorescent protein (DD-YFP) in medaka, the open reading frame of EGFP in pDS-Act1
[21] was replaced with the fusion ORF of pBMN-L106P-YFP [8] using NcoI and NotI. The
resulting plasmid was termed pDS-actb-DD-YFP (S1 and S2 Files) and contains endogenous
actb sequences of the medaka driving the DD-YFP expression.
Transgenesis and identification of founders
Transgenic fish were generated by microinjection of transposase mRNA and plasmid pDS-
actb-DD-YFP into 1-cell stage embryos of the strain d-rR.YHNI. The methodological details of
the Ac/Ds system in medaka have been described earlier [21, 22]. Embryos were incubated in
embryo culture medium at 26°C until hatching. Larvae were transferred to flow-through tanks
and raised to maturity.
Founder individuals were then mated to each other or to non-transgenic fish. The individu-
als inheriting the transgene were identified either by the YFP expression in the offspring or by
genotyping for the transgene in genomic DNA samples (F1 and later generations). Primers for
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the amplification of the transgene were DD-Nar-Nco-F (ggcGCCATGGGAGTGCAGGTG
GAA, start codon of fusion ORF underlined) and EGFP-C-REV (ACGAACTCCAGCAGGAC
CAT, position 655–674 in YFP).
Identification of integration sites
Genomic DNA was isolated from larvae or from tail fin tissue of adult fish. Sequences adjacent
to the integration site were amplified by TAIL-PCR as described [21], sequenced and identified
in the ensembl database using the BLAT/BLAST algorithm (http://www.ensembl.org/; medaka
genome version 55.1i).
The Ensembl genomic sequences were used for primer design, matching sequences either on
both sides of the integration site (wild-type allele) or on the transgene and the adjacent genomic
region (transgenic allele). Individual fish were genotyped according to the respective integration
sites in the sub-line (S1 Table). Primers matching the Ds-sites in the transgene were DS5-1
(CCGTTTACCGTTTTGTATATCCCG) or DS3-1 (CGATTACCGTATTTATCCCGTTCG).
In vivo treatment and image analysis
Stock solutions (1–10 mM) of Shield-1 (kindly provided by TomWandless or Clontech’s
#632188) were dissolved in absolute ethanol and stored at -20°C. Fish were treated by addition
of stock solution directly to the water at 26°C. Up to 6 larvae were treated in a total volume of 3
ml tap water supplemented with 0.03% (w/v) sea salt, adult fish were treated in 20 ml condi-
tioned tap water per individual. The fish were fed every second day and the water was changed
after feeding.
For image analysis the fish were sedated with 100 mg/l MS-222 (E10521, Sigma) in tap
water and observed under a fluorescence stereomicroscope (Leica MZ10F) equipped with a
YFP filter set (510/20 nm excitation, 560/40 nm emission). Photographs were taken with a
monochrome digital camera (Zeiss MRm) and processed using Adobe Photoshop CS2 (Adobe
Systems Corporation). For quantification of fluorescence in larvae, the area of the whole speci-
men was defined in the bright field image and the intensity of fluorescence was determined as
the mean grey value of this area in the fluorescence image. Figures show original photographs
or colored overlays of bright field and fluorescence.
Western blot
After individual treatment, brain, liver and testis were sonicated in 1 ml RIPA buffer containing
protease inhibitors (cOmplete ULTRA, Roche, Germany) per 50 mg tissue. Each sample was
adjusted to the same protein concentration before Western blotting of a 10% SDS-PAGE gel
on a PVDF membrane. Rabbit polyclonal anti-GFP (1:5,000; ab290, abcam, Cambridge) and
HRP-conjugated anti-rabbit (1:7,500; #111-035-144; dianova, Germany) antibodies were used
at the indicated dilutions before immunodetection with chemiluminescence (Luminata forte
Western HRP substrate, Merck, Germany).
Flow cytometry
Primary testis cells were isolated and analyzed as described [17]. Shield-1 was present during
the isolation procedure in the same concentration as in the in vivo treatment. DNA content
(Hoechst 33342; 5 μg/ml; Life Technologies) and YFP fluorescence were analyzed using a
CyFlow Space flow cytometer (Partec, Germany) at wavelengths of 375/455 nm (Hoechst
stain) and 488/527 nm (GFP and YFP).
Shield-1 in Medaka
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Results
Functionality of the transgene
Sequences flanking the coding region of the cytoplasmic actin gene (actb; promoter, exon 1,
intron 1 and 3’UTR) led to a nearly ubiquitous expression of EGFP in transgenic medaka [21].
The plasmid pDS-actb-DD-YFP (S1 File) contains these endogenous regulatory elements driv-
ing the expression of the fusion protein DD-YFP [8]. To assay conditional expression, HEK-
293T cells were transfected with pDS-actin-DD-YFP, cultured for 24 hours and treated with
Shield-1. The HEK-293T cells showed a dose-dependent increase of yellow fluorescence after
Shield-1 treatment (0.1, 0.8 and 1 μM) and over time (1, 5, 24 h) with no visible fluorescence in
untreated cells (data not shown).
Establishment of transgenic lines
The microinjection of pDS-actin-DD-YFP and transposase RNA in embryos of the 1- or 2-cell
stage led to a typical mosaic transgenesis pattern that was visible after treatment of freshly
hatched larvae of the founder generation with 0.8 μM Shield-1 (not shown). Two founder
males showed particularly strong mosaic fluorescence patterns but only one was successfully
mated. The germline transmission rate of this founder male was not determined, but individu-
als of the F1 generation transmitted the transgene to over 80% of their progeny. Such a high
rate of transmission is indicative for multiple integrations. Seven different integration sites of
the transgene were determined by TAIL-PCR (S1 Table).
Establishment of line Ola-Tg(actin-DD-YFP)13
For the experiments we chose individuals with identical transgenic status to exclude position
effects (S2 Table). One individual fish being hemizygous for a single integration of the trans-
gene could be identified in the F3 generation. The sub-line Ola-Tg(actin-DD-YFP)13 was
established from this male that inherited only one out of seven possible integrations. Individu-
als of the F4 (hemizygous for the transgene) to the F6 generation (homozygous) were used for
the experiments. For Western blot analysis, 24 individual fish of Ola-Tg(actin-DD-YFP)13 of
the F4 generation were genotyped for the presence of the transgene on chromosome 13. The 14
positive individuals were considered to be hemizygous since the remaining 10 individuals had
no transgene in the genome. For flow cytometry analysis, hemizygous fish of Ola-Tg(actin-
DD-YFP)13 of the F5 generation were used.
Induction of YFP in fry and embryos
Induction in fry. Ten freshly hatched fry (F4 generation) per concentration were treated
with Shield-1. An induction of YFP could be observed within a few hours in transgenic fry (Fig
1). Each individual was genotyped after the experiment and the data of the transgenics were
used for the analysis of leakiness and the kinetics of induction in vivo. The presence of auto-
fluorescent yolk and leucophores defines the basal level of fluorescence observed in non-trans-
genic fish and transgenics, respectively (Fig 1C).
Kinetics and dose dependency. For the analysis of the induction kinetics, 10 individuals
per concentration were treated with 10, 100 or 1,000 nM Shield-1, respectively. The fluores-
cence was analyzed after 1, 5, 24 and 48 hours. After 48 hours, the inducer Shield-1 was
removed to test the reversibility of the induction after 72 and 96 hours (Fig 1A-1C). The fluo-
rescence increased over time after a single administration of Shield-1 and the induction was
concentration dependent (Fig 1D). Shield-1 led to a strong increase in fluorescence after 5 and
24 hours using 100 nM and 1,000 nM inducer, respectively. The fluorescence values were
Shield-1 in Medaka
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significantly different from the vehicle control (Fig 1D and S2 Fig). The induction reached a
dose-dependent, steady-state level after approximately 24 hrs. After withdrawal of Shield-1 at
48 hours the fluorescence decreased to basal levels within the following 48 hours in the larvae
treated with 10 or 100 nM Shield-1. Treatment with 1,000 nM Shield-1 caused a strong and
Fig 1. Kinetics of YFP induction in fry. Transgenic fries were treated with the indicated concentrations of
Shield-1 or 0.1% ethanol (vehicle). After 48 hours, the water was exchanged and the imaging was continued
up to 72 and 96 hours to monitor the reversibility of the induction. (A-C) Fluorescence images of a
representative individual treated with 100 nM Shield-1; dorsal view, head to the right. The faint fluorescence
seen in transgenic individuals after 1 hour (A) increases to maximum after 48 hours (B) and decreases to
background level after 96 hours of the experiment (C). (D) Fluorescence values (area fluorescence, arbitrary
units) after treatment of fry with the indicated concentrations of Shield-1. Data points of three individuals are
shown for the vehicle control, 5–6 individuals for the other groups (mean with standard deviation). The
images were taken over a period of 96hours with an exposure time of 10 seconds. The monochrome images
in A-C were colored for clarity.
doi:10.1371/journal.pone.0131252.g001
Shield-1 in Medaka
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significant induction as early as 1 hour, did not reach a steady state and failed to be fully revers-
ible within 48 hours (Fig 1D).
Leakiness. Non-induced individuals of the line Ola-Tg(actin-DD-YFP)13 (Fig 1D)
showed a weak fluorescence that is merely detectable by eye in the tail and somites (Fig 2A &
2B) but could be quantified by image analysis (Fig 2C & S2 Fig). The transgenic individuals
show twice the area fluorescence (arbitrary units) than non-transgenics at the beginning of the
analysis. Two factors contribute to the observed decrease of fluorescence. First, the yolk mass is
autofluorescent and is metabolically degraded over time in both groups. Second, the yolk is
enclosed by epithelia of the gut and epidermis. These epithelia are fluorescent in transgenic fry,
hence leading to a disproportional contribution to the total area fluorescence within the first 48
hours (Fig 2C). At the end of the experiment the fluorescence values of the two groups are
converging.
Induction in embryos. Shield-1 treatment of embryos led to an induction of fluorescence
in transgenic embryos (S1 Fig). However, the induction and degradation of YFP was observed
later in the embryo than in the fry. Probably the diffusion of Shield-1 through the chorion is
Fig 2. Background fluorescence in transgenic fry of Ola-Tg(actin-DD-YFP)13. The fluorescence of
hemizygous transgenic individuals treated with 0.1% ethanol and non-transgenic siblings was analyzed. (A)
non-transgenic fry, (B) transgenic, non-induced fry. Monochrome images were colored for clarity, head to the
right. (C) Box plot (25–75%), average (open square) and mean (line) of the fluorescence (arbitrary units) are
shown. The values are normally distributed (Kolmogorow-Smirnov-test) in all samples and are significantly
higher (asterisks, p0.05, ANOVA) for transgenics compared to non-transgenic fish within the first 72 hours
of the experiment.
doi:10.1371/journal.pone.0131252.g002
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leading to a delayed kinetics of uptake and removal as compared to the fast kinetics in hatch-
ling and fry, respectively.
Induction in adult medaka
Adult male and female individuals were treated with different concentrations of Shield-1 and
analyzed after 24 hours. The induced fluorescence was visible in toto, in brain and in gonads
(Fig 3 and S3 Fig). The induction of YFP in brain (Fig 3B) shows that Shield-1 effectively passes
the blood brain barrier. Other tissues like gills, gut, liver, kidney, spleen and heart also
responded to the treatment (not shown). We did not compare the fluorescence levels between
different organs due to their differences in cellular composition, thickness and autofluores-
cence, but the induction was dose dependent in all organs.
The stabilization of the DD-YFP fusion protein was confirmed in an immunoblot. Adult
fish were treated with different concentrations of Shield-1 and protein extracts were isolated
after different time points (S4 Fig). The fusion protein was detected with a polyclonal anti-YFP
antibody in brain and testis extracts but the strong unspecific signals of yolk proteins masked
the expected protein band in extracts of the ovary (not shown). The expected signal at 40 kD is
only present in the soluble proteins of transgenic fish proofing its identity. A single administra-
tion of Shield-1 leads to a faithful stabilization for at least 48 hours. From these data, no conclu-
sions can be drawn about the kinetics of protein protection, but YFP is stabilized after
induction and the level of protein is stable for 48 hours after treatment.
The gonadal stem cells of the medaka are located in the outer tubular compartment of the
testis and in the cradles of the ovary [23, 24]. Remarkably, these regions showed an inducible
YFP fluorescence after in vivo treatment (Fig 3C and S3 Fig). For the testis, we quantified the
induced fluorescence by flow cytometry (Fig 4). Primary testis cells were isolated from trans-
genic fish after 24 hours in vivo treatment. For comparison, cells of non-transgenic FLFII (Fig
4A) and cells of an oct4-EGFP reporter line that labels the stem cell fraction of the testis (Fig
4D) were isolated. Identical gates and filters were used for the analysis; the quadrants indicate
the background fluorescence (Q1, Q3) on the horizonzal axis and the cells size of the somatic
cells and pre-meiotic germ cells (Q1, Q2).
In primary testis cells of Ola-Tg(DD-YFP)13 a minimal, if any, increase of fluorescence
(Q2) is observed after ethanol treatment compared to the non-transgenic cells (Fig 4A & 4B).
A strong increase in fluorescence is induced by in vivo treatment with 1 μM Shield-1 for 24
hours (Fig 4C). The percentages of cells in Q1 and Q2 are similar those of FLF-Tg(oct4-EGFP)
18 cells (Fig 4D). The stem cells of this transgenic line are found in Q2 and show the highest
transgene expression in the spermatogonia [17]. The fluorescence of these cells decreases dur-
ing mitotic divisions and differentiation. In contrast, a strong induction of YFP is observed in
the smallest cells of the pre-meiotic cell population in Ola-Tg(DD-YFP)13 (Fig 4C). These cells
belong to the mitotically active type B spermatogonia. Post-meiotic cells do not show an ele-
vated fluorescence in all samples.
Discussion
The DD-Shield system is designed for the expression of a fusion protein that is efficiently
degraded in the absence of Shield-1. We have chosen the reliable promoter of the actb gene
[21] to express a DD-YFP fusion protein. This promoter is known to drive a nearly ubiquitous
expression with the exception of red blood cells and probably the highly autofluorescent mela-
nophores [21]. A certain variability of the expression level among cells and tissues still allowed
monitoring the kinetics and dose dependency of the DD-Shield system in the medaka in vivo.
Shield-1 in Medaka
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Fig 3. Induction of YFP in adult medaka. The fluorescence of non-transgenic adult fish and of transgenic
individuals of Ola-Tg(actin-DD-YFP)13 was photographed after the indicated treatment with vehicle only
(0.1% ethanol) or 1 μMShield-1, respectively. (A) Adult females are shown as combinations of 2 overlapping
photographs in toto; exposure time: 13 sec, scale bar: 5 mm. (B) Brains of the same individuals as in A;
exposure time: 21 sec, scale bar: 1 mm. (C) Testes of adult males show the strongest fluorescence at the
outer area at the end of the tubules (arrows); exposure time: 13 sec, scale bar 1 mm.
doi:10.1371/journal.pone.0131252.g003
Shield-1 in Medaka
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At concentrations ranging from 10 to 1,000 nM Shield-1 we observed a concentration
dependent level of induction. A low level of leakiness could be quantified in untreated individu-
als probably caused by the strong actb promoter. However, the efficient degradation of YFP
after withdrawal of 1,000 nM Shield-1 indicates highly active proteasomal degradation in
medaka. This degradation capability should minimize any effects of the transgene when weaker
promoters are used. The pharmacokinetics of Shield-1 was not analyzed with respect to absorp-
tion, metabolism and excretion. However, the in vivo treatment with 10–100 nM Shield-1 leads
to a faithful and revertible induction of the transgene in medaka.
The administration of Shield-1 to the water is the most convenient way to expose fish from
early embryonic stages to adults. We did not test the alternative ligand AquaShield-1 with opti-
mized aqueous solubility that recently became available. The induction kinetics of Shield-1 in
vivo is fast and dose dependent in medaka. The fact that gills and the gut show the strongest
induction in larvae could be due to the direct contact with the inducer or the high DD-YFP
expression level in these epithelia. A stronger fluorescence in the gut has already been observed
for non-inducible EGFP using the same promoter sequences [21]. Shield-1 crosses the blood
brain barrier efficiently. It is also active in the stem cells of the testis. This is remarkable since
Fig 4. Induced fluorescence of testis cells analyzed by flow cytometry. Primary testis cells of hemizygous Ola-Tg(DD-YFP)13 were analyzed for size
(FSC), fluorescence (GFP) and DNA content (Gate R1; Hoechst staining, not shown). The quadrants Q1 and Q2 contain cells with a DNA content of 2C to
4C, i.e. somatic cells and germ cells prior to meiosis. The plots show the data of 129–154,000 single cells. (A) The fluorescence in a sample of a non-
transgenic FLFII and was plotted against the cell size. (B) In the non-induced control virtually no additional fluorescence is observed in Q2 compared to FLFII.
(C) Treatment with 1 μMShield-1 causes a strong induction of fluorescence in the largest cells that comprise the stem cell fraction. Absolute fluorescence
and number of cells in Q2 are increased. (D) For comparison, the GFP-positive stem cells in FLF-Tg(oct4-EGFP)18 are shown [17]. In this line, the
fluorescence decreases during diffentiation (arrow). In contrast, a cell fraction of similar size has an elevated fluorescence after induction (arrow in C). These
cells represent the mitotically active type B spermatogonia that actively transcribe the actb-driven DD-YFP but not the oct4-driven EGFP.
doi:10.1371/journal.pone.0131252.g004
Shield-1 in Medaka
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gonadal cells failed to respond to heat shock treatment in earlier experiments [4]. After treat-
ment with Shield-1, the fluorescence pattern of primary testis cells resembles the pattern of
oct4-EGFP expressing cells in flow cytometry. Undifferentiated spermatogonia divide slowly
but proliferate actively during spermatogenesis. Oct4-EGFP is expressed in the spermatogonia
of the medaka and the stem cell-specific fluorescence decreases during mitotic division and dif-
ferentiation of the germ cells [17]. In contrast to oct4-EGFP expressing cells, the differentiating
fraction of actb-DD-YFP cells has an increased fluorescence after induction with Shield-1 (Fig
4C and 4D). Cytoplasmic actin is an important factor for spindle formation in mitosis and mei-
osis, mostly studied on the level of protein dynamics [25]. Conceivably, an elevated expression
of actin precedes this proliferative burst in the respective cell fraction and the actb-driven
DD-YFP expression is simultaneously activated in our experimental setting. Irrespective of this
specific pattern, DD-Shield-1 allows the targeting of germ cells in future experiments using
conditional protein expression.
The use of a single transgene is convenient since transgenesis and stock management is
facilitated. It might also be of interest to fuse the destabilizing domain to an endogenous gene,
resulting in a conditional knock down/ knock out of the target gene. This has been reported for
human cells in vitro, in which the first exon of TCOF1 was replaced by a DD-tagged sequence
[26]. Park et al. achieved this genomic engineering by CRISPR/Cas9-mediated homologous
recombination and a donor template coding for a resistance cassette and the DD-fusion
sequence [27]. In a similar approach, Chen et al. (2013) introduced a hygromycin resistance
cassette to the ben-1 locus in Caenorhabditis elegans and isolated resistant individuals of the F2
generation [28]. These selection procedures make an estimation of the efficacy difficult for tele-
osts, but CRISPR-Cas9 has been already used to introduce sequence modifications in target
genes of zebrafish [29] and medaka [30]. Therefore, the targeted knock-in of the destabilizing
domain to the gene of interest in vivo is principally possible. However, Shield-1 is an expensive
inducer when adult individuals are to be treated. As an alternative, the destabilizing domain
derived of the bacterial dihydrofolate reductase [31] could be used. Its inducing molecule tri-
methoprim is less expensive and is an approved drug crossing the blood brain barrier when
administered via the drinking water to rats [32]. Therefore, in the case of establishment in
medaka, two excellent systems would be available in the future.
From our data we can conclude that the DD-Shield system in medaka is a valuable tool for
conditional protein expression in vivo. Its major advantage is the induction on the level of the
protein showing a fast and reversible response that allows the fine tuning of active protein lev-
els and exceeds the control by induced transcription only.
Supporting Information
S1 File. Graphic map of pDS-actb-DD-YFP. The sequence was combined from databases (vec-
tor) and sequencing results during cloning. The map was created with Serial cloner version 2.6.1.
(TIF)
S2 File. Sequence of pDS-actb-DD-YFP in GenBank format. The sequence was combined
from databases (vector) and sequencing results during cloning. The file was created with Serial
cloner version 2.6.1.
(TXT)
S1 Table. Integration sites of the transgene and primers for genotyping. The sub-lines of Ola-
Tg(actin-DD-YFP) were named by the chromosome carrying the integration, e.g. Ola-Tg(actin-
DD-YFP)13. The chromosome cannot be identified in the case of repetitive sequences (Repeat 4).
(PDF)
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S2 Table. Genotypes of individual fish analyzed in this work. Individuals #1–19 were of the
F2 generation, #20–23 of F3. Only individual #21 had a single integration (C13) and was used
for further breeding and analysis of embryos. () marks the female individuals used for induc-
tion in S3 Fig.
(PDF)
S1 Fig. Induction of YFP in embryos. Embryos homozygous for the integration of DD-YFP
on chromosome 13 (F6) were treated at blastula stage with vehicle only (A) or 1 μM Shield-1
(B, C) and photographed every 24 hours; dorsal view, head to the left. Withdrawal of Shield-1
after 48 hours led to a reduction of fluorescence (B’). Images were taken with fixed exposition
time of 11 s (1 dpf), 4 s (2 dpf) and 500 ms (3 & 4 dpf), respectively. The fluorescence in row A
(1 dpf– 4 dpf) is merely visible. Dpf: days post fertilization.
(TIF)
S2 Fig. Statistical analysis of fluorescence values after 24 and 48 hours of treatment.
Box plots (25–75%), average (open square) and mean (line) of the fluorescence (arbitrary
units) are shown for each sample. A significant increase of fluorescence (asterisks, p0.05,
ANOVA) can be observed between the vehicle control and the 100 nM and 1 μM samples,
respectively. 10 nM Shield-1 did not lead to a significant increase in fluorescence as compared
with the vehicle control, but the vehicle control is significantly different from the non-trans-
genic sample.
(TIF)
S3 Fig. Photographs of adult medaka and organs after induction with Shield-1. A non-
transgenic individual, non-induced control (0.1% ethanol) and treatment with 10 nM or 1 μM
Shield-1 for 24 hours are shown. Adult females with integrations of the transgene on chromo-
somes 15 and 19 (Table S4) were treated as indicated. The fluorescence (YFP channel) was
photographed with a monochrome camera at a constant exposure time of 13 sec.
(TIF)
S4 Fig. Western blot and immunodetection of YFP in brain and testis. Total protein of male
brain (A) and testis (B) was isolated after the indicated treatment. A non-transgenic control
fish does not show the expected signal at approximately 40 kD (white asterisks). The transgenic
fish show signals at different intensities: the vehicle control (0.1% ethanol) is not negative but
the induced fish show a clear stabilization of DD-YFP fusion proteins after 24, 48 and 96
hours. The polyclonal anti-GFP antibody has a high cross reactivity to YFP and other medaka
proteins, this served as loading control. The HRP-coupled secondary antibody used for chemi-
luminescence detection did not cross-react (not shown).
(TIF)
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